In short
Clinical trials are investigating Rusfertide in people with polycythemia vera. The main goal is to see whether it can help maintain hematocrit control and how well it works compared with placebo. This article focuses on the study design, phase, participants, and outcomes being measured.
Key points
- Clinical trials are studying Rusfertide in people with polycythemia vera. The provided trial is a Phase 3 study, which means it is a later-stage trial with a larger group of participants. The main purpose is to evaluate safety and efficacy while keeping hematocrit under control. The study compares Rusfertide with placebo. Its main endpoint looks at whether participants avoid phlebotomy eligibility from Week 20 through Week 32. The trial plans to enroll 250 people.
Trial overview
The provided clinical trial is a Phase 3 study of Rusfertide in people with polycythemia vera, a blood disorder listed in the source data. The study is designed to evaluate the safety and efficacy of Rusfertide in maintaining hematocrit control.
Study design and treatment groups
This is an interventional study, which means researchers assign a treatment and then measure the results. The trial includes Rusfertide dose groups listed as 10 mg, 20 mg, 30 mg, 45 mg, and 60 mg, all given by subcutaneous use, and a placebo group designed to match PTG-300 for injection.
The source also notes that the placebo is a lyophilized powder formulation with the drug substance omitted. Lyophilized powder means a freeze-dried form that is prepared for injection.
Who can participate
The trial is for subjects with polycythemia vera. The provided data do not list other entry rules, such as age limits, prior treatments, or lab thresholds for joining the study.
What is being measured
The main outcome is the proportion of subjects who achieve a response from Week 20 through Week 32 inclusive. In this study, a response means absence of phlebotomy eligibility.
Phlebotomy eligibility is defined in the source as either a confirmed hematocrit of 45% or higher that is at least 3% above the baseline hematocrit, or a hematocrit of 48% or higher. Baseline hematocrit means the value right before randomization at Week 0.
In simple terms, the study is checking whether Rusfertide helps more people stay below the level where blood removal would be needed.
Study status and size
The trial status is listed as Authorised. The planned enrollment is 250 participants, which is the number of people the study aims to include.
Because this is a Phase 3 study, it is a later-stage trial that usually helps show how well a treatment works in a larger group while also watching safety. In this case, the focus is on whether Rusfertide can maintain hematocrit control better than placebo in polycythemia vera.